the global market for antibody-drug conjugates was rated at $4,990.5 million in 2021. It is projected to be worth $33,140.3 million by 2030, registering a CAGR of 26.7% from 2022 to 2027. Antibody-drug conjugates are the anticancer drugs that offer one of the fastest growing treatments for cancer patients, able to exploit the specificity of monoclonal antibodies towards antigens targeted to release potential cytotoxic drugs with increased activity and decreased toxicity compared to chemotherapies. The market is expected to show lucrative growth over the forecast period. It is primarily driven by the increasing incidence of cancer, the growth of the geriatric population, and changing lifestyles around the world. The growth of the market is mainly supported by the technological advancements and the recent development of healthcare in the world.
Moreover, field research studies and rapid product launch are also driving the market growth. For example, in 2019 the United States Food and Drug Administration approved three antibody-drug conjugates for various types of cancer. Thus, growing aging population and incidence of cancer coupled with advancements in the field of antibody-drug conjugates are expected to drive the revenue growth of the market studied; Strict government regulations and high costs associated with manufacturing may restrain the market growth over the forecast period.
Get a PDF for more professional and technical information: https://www.marketstatsville.com/request-sample/antibody-drug-conjugates-market
Thus, growing aging population and incidence of cancer coupled with advancements in the field of antibody-drug conjugates are expected to drive the revenue growth of the market studied; Strict government regulations and high costs associated with manufacturing may restrain the market growth over the forecast period.
covid–19 Global Antibody-Drug Conjugates Market Impact
Due to the high transmission of COVID-19, many countries have suffered many losses and continue to impose them on their economies and health systems. Many countries were in lockdown and suspended trade with other countries, implemented travel restrictions, etc., causing the market capitalizations of major companies around the world to decline. However, the situation is gradually improving with the increase in the vaccination rate.
According to the Cellular and Bioengineering Journal article titled “The Impact of COVID-19 on Cancer Risk and Treatment”, published in August 2020, reports indicate that cancer patients are at high risk of developing serious complications following of an infection with the SARS-CoV-2 virus. He also reports that immune dysregulation and chronic inflammation may be potential drivers of serious outcomes in COVID-19 positive cancer patients. Thus, the increased complexity in cancer patients generates the need for advanced and effective therapy for the treatment and thus drives the growth of the antibody-drug conjugates market over the forecast period.
Global Antibody-Drug Conjugate Market Dynamics
Drivers: Growing geriatric population
With the increase in life expectancy due to improved healthcare facilities around the world, every country in the world is experiencing changes in its demographic structure, and the share and growth of the elderly population is increasing dramatically. However, as the elderly population is at an immense risk of being affected by cancer, the growth in the geriatric population is expected to drive the growth of the market studied.
Additionally, the American Cancer Society report titled Cancer Facts and Figures 2021 shows that the risk of developing cancer increases with age. The same source also reports that 80% of cancers in the United States are diagnosed in people 55 or older. Thus, the increase in the geriatric population is expected to contribute significantly to the growth of the market.
Constraints: Strict government regulations
The strict regulatory framework exists for antibody-drug conjugates, which ultimately delays their rapid approval and market introduction. Many countries and federal entities have laws that restrict industry-wide sales. Hence, it may impact the growth of Antibody Drug Conjugates over the forecast period.
According to the MDPI Journal article titled “Advances and Limitations of Antibody Drug Conjugates for Cancer” published in July 2021, reports that the Therapeutic Goods Administration (TGA), European Medicines Agency (EMA) and Food and Drug Administration of United States has strict guidelines for stability testing prior to registration and transportation of prescription drugs. Because temperature fluctuations can affect aggregation, the guidelines recommend that real-time data be provided to substantiate how long a drug product can be left out of the refrigerator before being brought back to its recommended temperature.
You can buy full [email protected] https://www.marketstatsville.com/buy-now/antibody-drug-conjugates-market?opt=2950
Scope of Antibody-Drug Conjugates
The study categorizes the Antibody-Drug Conjugates market based on product, technology, target, application, and end-users regionally and globally..
By product type (Sales, million USD, 2017–2030)
- Other type of product
By Technology Insights (Sales, million USD, 2017–2030)
- Cleavable linker
- Non-cleavable linker
By Outlook target type (Sales, million USD, 2017–2030)
- CD30 antibody
- HER2 antibody
- Other target types
By Outlook app (Sales, million USD, 2017–2030)
- Breast cancer
- Ovarian cancer
- Lung cancer
- Skin cancer
- Brain tumour
- Other Apps
From end-user perspectives (Sales, million USD, 2017–2030)
- Hospitals and specialized cancer centers
- Other end users
Outlook by region (Sales, million USD, 2017–2030)
- North America (United States, Canada, Mexico)
- South America (Brazil, Argentina, Colombia, Peru, Rest of Latin America)
- Europe (Germany, Italy, France, United Kingdom, Spain, Poland, Russia, Slovenia, Slovakia, Hungary, Czech Republic, Belgium, Netherlands, Norway, Sweden, Denmark, Rest of Europe)
- Asia Pacific (China, Japan, India, South Korea, Indonesia, Malaysia, Thailand, Vietnam, Myanmar, Cambodia, Philippines, Singapore, Australia and New Zealand, Rest of Asia Pacific)
- The Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa, North Africa, Rest of MEA)
The Kadcyla Segment expected to account for the largest market share, by product type
Based on product type, the global Antibody-Drug Conjugates market is segmented into Adcetris, Kadcyla and other product types. In 2021, Kadcyla segment accounted for the largest market share of 49.1% in the global market for antibody-drug conjugates. Kadcyla (API: ado-trastuzumab emtansine) is currently available as an injectable for intravenous use only. The drug got its first approval in the United States in 2013, and it is currently one of the leading drugs in the market, due to its high potency and effectiveness in many indications.
The increased demand for Kadcyla has been driven by its use in the context of early breast cancer and ongoing clinical trials. In June 2020, NICE published final guidance supporting NHS use of Roche’s Kadcyla for the adjuvant treatment of human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in people who have already had treatment to shrink their tumor but have residual disease in the breast or surrounding lymph nodes before surgery to remove the tumor.
Access the full description of the report, Contentsfigure chart, graph, etc. @ https://www.marketstatsville.com/table-of-content/antibody-drug-conjugates-market
North America represents the highest CAGR over the forecast period
North America, Asia-Pacific, Europe, South America, Middle East & Africa are the regions into which the global antibody-drug conjugates market has been segmented. Globally, North America is estimated to hold the highest CAGR of 27.4% in the global Antibody-Drug Conjugates market during the forecast period. The region includes countries such as the United States, Canada, Mexico.
After North America, Europe is the fastest growing region with a CAGR of 26.7% during the forecast period. Factors such as an increasing incidence of cancer, increasing geriatric population, and increasing investment in research and development are some of the factors driving the antibody-drug conjugates market in Europe. According to estimates from the Globocan 2020 report by the International Agency for Research on Cancer, there were approximately 628,519 new cases of cancer in Germany in 2020. According to the report, the most common cancers in Germany are breast cancer, lung cancer, prostate and colon cancer. The high incidence of cancer indicates the need to develop new therapies such as antibody-drug conjugates that can effectively reduce the burden, due to which there is expected to be scope for market growth.
Request for Report Description @ https://www.marketstatsville.com/antibody-drug-conjugates-market
Main market players
Antibody-drug conjugates market is slightly concentrated in nature with few global players operating in the market such as Novartis AG, Takeda Pharmaceutical Company Limited, F. Hoffman-La Roche Ltd., Pfizer, Inc., Seattle Genetics Inc. , Genentech Inc., Immunogen Inc., Progenics Pharmaceuticals Inc., Immunomedics, Inc., Bayer Healthcare Pharmaceuticals., Agensys, Inc., Concortis Biotherapeutics, Celldex Therapeutics Inc., Sanofi SA and Synthon Holding BV